Posters

An Assessment of the Clinical Evidence in Economic Evaluations Submitted to the Common Drug Review (CDR)

• Catherine Jordison

Burden of Human Papillomavirus Infection across Canada: A Systematic Review

• Ba’Pham

Clinical Evidence Available for Expensive Drugs for Rare Diseases: Challenges for Reimbursement Recommendations

• Sandy Pagotto

The Concurrent Use of Cholinesterase Inhibitors and Anticholinergic Medications in Patients with Alzheimer's Disease: Comparison of Alberta and Saskatchewan

• Alison Supina

The Cost-Effectiveness of Nucleic Acid Amplification Testing in the Detection of Acute Hepatitis C Virus Infection

• Hla Hla Thein

Cost-effectiveness of Long-term Management of Heartburn

• Ron Goeree

Demographic and Clinical Predictors of Quality of Life in Prostate Cancer Patients

• Murray Krahn

Developing Criteria and Decision-Making Processes for Prioritization of Health Technologies at the Local Level

• Paule Poulin

Development of an Undergraduate Level University Course and a 1-Day Workshop on the Principles of Health Economics and HTA to Increase Health Practitioner Knowledge

• Larry Lynd

Drug Evaluation Unit: A Structure to Support Evidence-based Policy Decisions and Educational Interventions

• Pamela McLean-Veysey

e-Therapeutics Drug Therapy Decision Tools

• Janet Cooper

Expansion of Universal Newborn Screening for Inborn Errors in Metabolism and Cystic Fibrosis: An Evidence Informed Approach used in Canadian Province

• Henry Borowski

Interactive HTA Education Program for Health Care Practitioners in a Local Residency Program

• Tyron Donnon

Lay Perceptions of Genetic Testing

• Holly Etchegary

Methodological Issues in Meta-Analysis of Chronic Diseases: Diabetic Retinopathy in Type 2 Diabetes

• Stephanie Duench

Narcotic Use in the Five University Health Centers in Québec: A Descriptive Analysis from the Programme de Gestion Thérapeutique des Médicaments (PGTM)

• Marie-Claude Michel

Natural History of Chronic HCV Infection Obtained through Injection Drug Use: A Bayesian Meta-Analysis

• Ava John-Baptiste

Non-Patented Prescription Drug Price Monitoring and Reporting

• Ron Corvari

A Pilot Survey Examining the Updating Experiences of Health Organizations that Fund and/or Conduct Systematic Reviews Research

• Chantelle Garritty

Preschool Vision Screening

• Lesley Dunfield

Prostate Cancer: Predictors of Phase-Specific and Lifetime Costs

• Steven Carcone

Providing Evidence on disease Prevention through the Health Technology Inquiry Service

• Rhonda Boudreau

Revascularization and Survival Trends of Canadian Acute Myocardiol Infraction (AMI) patients, 1995/96 to 2003/04

• Helen Johansen

A Review of Approaches to Considering Ethical, Legal, and Social Issues in Health Technology Assessment: Application to Newborn and Prenatal Screening

• Beth K. Potter

Review of Risk Issues Associated with Reuse of Single Use Devices (SUDS)

• Sandra Berzins

A Review of Sources of New Drug Information Used for Horizon Scanning

• Christine Perras

The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond

• Angela Rocchi

Are Short-Acting Insulin Analogs Cost Effective: An Economic Review

• Huimin Li

Stimulant Use in New Brunswick

• Christine Albino

Systematic Review Publication Bias: An International Survey

• Andrea Tricco

A Taxonomy of Interventions Directed at Consumers to Promote Evidence-Based Prescribing and Drug Use: A Tool for Evidence-Based Decision-Making

• Nancy Santesso

Time Horizon Bias in Economic Evaluations

• Beate Sander

The Use of Communication Technologies to Disseminate Research Findings within Drug Policy Groups

• Mowafa Househ

Weighting Clinical Trial Endpoints to Reflect Relative Importance

• Ahmed Bayoumi

Ethics in Canadian Health Technology Assessment: A Descriptive Review

• Deirdre DeJean, Mita Giacomini